- Home
- KALV vs DPG Comparison
KALV vs DPG Comparison
Compare KALV & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- DPG
- Stock Information
- Founded
- KALV N/A
- DPG 2011
- Country
- KALV United States
- DPG United States
- Employees
- KALV N/A
- DPG N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- DPG Trusts Except Educational Religious and Charitable
- Sector
- KALV Health Care
- DPG Finance
- Exchange
- KALV Nasdaq
- DPG Nasdaq
- Market Cap
- KALV 796.4M
- DPG 462.7M
- IPO Year
- KALV N/A
- DPG N/A
- Fundamental
- Price
- KALV $13.38
- DPG $12.41
- Analyst Decision
- KALV Strong Buy
- DPG
- Analyst Count
- KALV 8
- DPG 0
- Target Price
- KALV $26.43
- DPG N/A
- AVG Volume (30 Days)
- KALV 984.5K
- DPG 150.1K
- Earning Date
- KALV 09-11-2025
- DPG 01-01-0001
- Dividend Yield
- KALV N/A
- DPG 9.09%
- EPS Growth
- KALV N/A
- DPG N/A
- EPS
- KALV N/A
- DPG N/A
- Revenue
- KALV $1,426,000.00
- DPG N/A
- Revenue This Year
- KALV N/A
- DPG N/A
- Revenue Next Year
- KALV $213.43
- DPG N/A
- P/E Ratio
- KALV N/A
- DPG N/A
- Revenue Growth
- KALV N/A
- DPG N/A
- 52 Week Low
- KALV $7.30
- DPG $7.90
- 52 Week High
- KALV $17.28
- DPG $13.58
- Technical
- Relative Strength Index (RSI)
- KALV 43.21
- DPG 37.00
- Support Level
- KALV $13.26
- DPG $12.46
- Resistance Level
- KALV $14.25
- DPG $12.77
- Average True Range (ATR)
- KALV 1.03
- DPG 0.13
- MACD
- KALV -0.15
- DPG -0.03
- Stochastic Oscillator
- KALV 3.70
- DPG 0.00
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting from a high level of current income, with an emphasis on providing tax-advantaged dividend income.